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Abstract: The majority of neurologically symptomatic cerebrospinal fluid HIV-1 escape cases are 
connected with resistance-associated mutations and potentially explained by low cerebrospinal fluid 
antiretroviral concentrations. However, there are still significant knowledge gaps regarding the 
physiopathology and long-term management of neurosymptomatic viral escape. We report a case of 
Parkinson-like syndrome following cerebrospinal fluid HIV-1 escape in a 40 years-old female 
patient with an history of persistent low-level plasma viremia under treatment. No resistance-
associated mutations, high viral diversity (env deep sequencing), adequate pharmacokinetics, 
atypical CD3-CD14-CD4+CD5-CD2-/+CD7-/+ lymphocytes, low level Epstein-Barr virus 
replication and white matter autoimmune reactivity were observed in the cerebrospinal fluid. 
Antiretroviral regimen modification led to rapid clinical and radiological improvements. This case 
may increase the current uncertain knowledge on the origin of cerebrospinal fluid HIV-1 and 
illustrates the consequences of uncontrolled compartmental viral replication; it also highlights the 
relevance and persistence of immune activation and the possibility of various detrimental 
mechanisms underlying neurosymptomatic viral escape. 
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Manuscript: 
Introduction 
Human Immunodeficiency Virus (HIV) has been associated with various neurological disorders 
(Ferretti et al. 2015). Despite the striking effectiveness of highly-active antiretroviral therapy 
(HAART), several cases of cerebrospinal fluid (CSF) viral escape (CVE) have been reported (Edén 
et al. 2010; Edén et al. 2016; Canestri et al. 2010; Peluso et al. 2012). CVE refers to cases where 
subjects have CSF HIV-RNA 0.5-1 Log10 greater than the corresponding plasma HIV-RNA or still 
detectable despite plasma undetectability (Ferretti et al. 2015). This condition is found in 10-36% of 
treated HIV-positive patients (Edén et al 2010; Edén et al. 2016), and it has been associated with 
long history of infection, severe immune depletion and incomplete adherence to HAART (Edén et 
al. 2010; Edén et al. 2016; Nightingale et al. 2016; Peluso et al. 2012). Such circumstances, coupled 
with inadequate antiretrovirals’ penetration, may favour the selection of resistance-associated 
mutations (RAMs) within the central nervous system (CNS) leading to CVE (Ferretti et al. 2015). 
Most CVE are asymptomatic, probably representing the CSF equivalent of plasma viral blips with 
debated clinical significance (Edén et al. 2016). Nevertheless, a few cases of neurosymptomatic 
CVE have also been reported (Canestri et al. 2010; Peluso et al. 2012), and the most common sign 
was cerebellar ataxia (Canestri et al. 2010). In almost all of these cases RAMs were observed 
(Canestri et al. 2010; Peluso et al. 2012), supporting the hypothesis that low CNS drug 
concentrations allows their selection and facilitates CVE. Such neurological syndromes can usually 
be reverted by modifying treatment including drugs with better CNS penetration and activity 
(Ferretti et al. 2015; Canestri et al. 2010; Peluso et al. 2012). However, there are still significant 
knowledge gaps regarding the physiopathology and long-term management of neurosymptomatic 
CVE. We here report a case of neurosymptomatic HIV-1 escape without CSF RAMs that 
underwent extensive diagnostic assesment. 
The Case 
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A 40-years-old woman was diagnosed with HIV-1 infection in the 90s; she started zidovudine plus 
lamivudine and K70R and M184V were rapidly selected. In the following years, she reported poor 
adherence to HAART and she later discontinued treatment. In 2008 she presented with 
Pnemuocystis jirovecii pneumonia (13 CD4+ T-cells/uL; plasma and CSF HIV-RNA 557351 and 
2545 cp/mL). No RAMs were observed in either samples, viruses were R5-tropic and brain 
magnetic resonance (MRI) resulted normal. Maraviroc, atazanavir/ritonavir and tenofovir-
disoproxil-fumarate were started. Six months later her CD4+ count was 579 cells/uL, while her 
virological response was suboptimal due to persistent low-level plasma viremia, despite self-
reporting good adherence. Atazanavir/ritonavir was replaced by once-daily darunavir/ritonavir 
following the observation of N88S/G73S on protease gene. In 2015, she developed headache, 
dizziness, severe gait abnormalities and significant unintentional tremors, depicting a Parkinson-like 
syndrome. Neurological examination revealed lower-limb weakness, tremors at rest, cogwheel 
rigidity, slow parkinsonian gait and alterations in deep tendon reflexes. Brain MRI was abnormal 
and consistent with findings usually observed in cerebral, cerebellar and brainstem regions of 
symptomatic CVE cases (Ferretti et al. 2015; Canestri et al. 2010; Peluso et al. 2012) (Fig.1). CSF 
examination revealed mononuclear pleocytosis, elevated proteins and normal glucose. CSF-serum 
albumin ratio was within the age-adjusted normality suggesting no blood-brain barrier impairment, 
while CNS immune activation was significant (elevated CSF neopterin, IgG index and intrathecal 
IgG synthesis; Tab.1). CSF cytofluorimetry showed the presence of an expanded subpopulation of 
atypical CD3-CD14-CD4+CD5-CD2-/+CD7-/+ lymphocytes (2.9% of CSF lymphocytes; see 
Supplementary Fig.1). CSF cultures and examinations for opportunistic infections were negative, 
although CSF EBV-DNA was 82 cp/mL; CSF and plasma HIV-RNA were 7566 cp/mL and 90 
copies/mL. CSF genotypic testing showed no RAMs. Interestingly, an indirect immunofluorescence 
assay on primate cerebellum sections evidenced the patient’s CSF binding on white matter 
structures (in a CV2/CRMP5-like pattern) associated to a pericellular synaptic reactivity around 
Purkinje cells (see Supplementary Fig.2). No known antigens were identified by commercially 
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available immunoblot tests (Hu, Ma2, NMDA) and myelin oligodendrocyte glycoprotein antibodies 
were negative on serum and CSF. We also isolated CSF HIV-RNA and performed 300 base pair, 
paired-end Illumina MiSeq deep sequencing of the V1-V3 region of the HIV env using the Primer 
ID method (Zhou et al. 2015). The analysis revealed a diverse viral population that likely evolved 
within the CNS over many generations (Fig.2). Antiretrovirals CSF concentrations were detectable 
(Tab.1) and similar to what previously described (Best et al. 2012; Calcagno et al. 2015). Her 
regimen was changed to twice-daily darunavir/ritonavir, raltegravir and etravirine, taking into 
account plasma RAMs and CSF inhibitory quotients (Calcagno et al. 2015). Three months later full 
clinical recovery was observed; a significant improvement in brain MRI was also recorded (Fig.1). 
Virological and inflammatory biomarkers at the time of escape and 3-9 months later are reported in 
Tab.1. 
Discussion 
Neurosymptomatic CVE is characterized by the acute/subacute onset of new neurological signs in 
HAART-treated patients presenting with discordance between plasma and CSF HIV-RNA when no 
other clinical condition may explain such manifestations (Ferretti et al. 2015). Our patient had 
virtually all the risk factors for CVE (Edén et al. 2010; Edén et al. 2016; Nightingale et al. 2016; 
Peluso et al. 2012): a very low CD4+ nadir, a long history of infection and antiretroviral treatment, 
previous HAART interruption and recurrent low-level plasma viremia. Furthermore, the CSF 
results and the typical white matter hyperintensities on T2-weighted and FLAIR sequences were 
similar to previous symptomatic CVE (Ferretti et al. 2015; Canestri et al. 2010; Peluso et al. 2012). 
Nevertheless, while the majority of neurosymptomatic CVE are associated with RAMs (Ferretti et 
al. 2015; Nightingale et al, 2016; Canestri et al. 2010; Peluso et al. 2012), in our case we 
documented no CSF drug resistance. Such a pattern may be generated by antiretrovirals not 
reaching inhibitory levels throughout the brain tissues or having poor activity in infected target cells 
(Calcagno et al. 2015; Gray et al. 2013). Despite CSF concentrations of our patient were above the 
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in vitro inhibitory concentrations (Best et al. 2012; Calcagno et al. 2015), they are just surrogates of 
CNS antiretrovirals activity. Lacking CNS tissues pharmacodynamics/pharmacokinetic data, we 
cannot rule out that our patients’ antiretrovirals had a reduced concentration/activity in some CNS 
HIV-infected cells (Gray et al. 2013). Moreover, the genetic diversity of the CSF HIV-1 population 
we observed indicates that it was produced by a large number of productively infected cells within 
CNS, but it was unclear whether it was due to ongoing viral replication during HAART or to 
persistent production within CNS without replication.  
To our knowledge, no reported symptomatic CVE was investigated for immunoreactivity against 
CNS antigens. Rather than being the cause of neurological syndromes, this phenomenon is likely 
due to brain cells and blood-brain barrier damage in an inflammatory milieu since immune 
hyperactivation may indeed lead to such non-sense production of autoantibodies (Lackner et al. 
2010). Compartmental immune activation is a striking feature of symptomatic CVE (Spudich 
2016), and in our patient it persisted for months despite viral control (Tab.1). Nevertheless, similar 
auto-reactivity has also been found to correlate with CSF HIV-RNA and HIV-associated 
neurocognitive disorders in cases without prominent neurotoxic inflammation (Lackner et al. 2010), 
so that further studies are needed to assess the conceivable pathogenic role of such findings in HIV-
related neurological disorders. Lastly, this is also the third case of neurosymptomatic CVE with 
concurrent low-level CSF EBV-DNA (Peluso et al. 2012). We do not know if the atypical CSF T-
cell subpopulation we reported was related to such a replication, to the CVE itself or to some other 
hidden ongoing process; the subpopulation was no more observed after both HIV-RNA and EBV-
DNA disappearance. It has been speculated that some cases of CVE may be secondary to other 
CNS infections or inflammatory process leading to an influx of HIV-infected leukocytes carrying 
the virus into CNS (Ferretti et al. 2015). From this point of view, CVE may also not be always the 
primary cause of neurological syndromes, but rather an accompanying epiphenomenon (Ferretti et 
al. 2015).  
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In conclusion, CVE is most easily explained by the use of regimens that reach inadequate levels in 
CNS areas where HIV replicates, that have poor activity in CNS cells and/or by the presence of 
drug-resistant viruses within CNS. Symptomatic CVE was reversible once HAART was improved. 
This observation coupled with the absence of RAMs and the diversity of the CSF viral population 
suggests that the escape of our patient was due to ongoing viral replication in CNS regions where 
drug levels were low or her regimen had poor activity. Moreover, this case points out that more than 
one factor is likely involved with the development of neurosymptomatic CVE and that 
disproportionate immune response may be associated with acute neurological signs and it may 
slowly decline after viral control. It also highlights the current lack of certainty about the 
physiopathology of this uncommon but serious clinical entity, underlining the need for better 
understanding CNS viral compartmentalization and the inhibitory activity of antiretrovirals in all 
CNS cell types.  
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Fig 1 Brain magnetic resonance imaging on long-TR sequences at the time of escape (left 
panel), three (middle panel) and nine (right panel) months later  
Extensive signal abnormalities in the form of patchy asymmetrical feeble hyperintensities on long-
TR sequences involving both caudate nuclei and thalami, left pallidum, diffusely the subcortical 
white matter of both temporal lobes, cerebellar peduncles and midbrain until pontobulbar junction 
were observed at the onset of CVE (left panel). After gadolinium administration, the lesions were 
non-enhancing. The extension and intensity of these abnormalities decreased over time after 
HAART modification: basal ganglia presented normal signal on all sequences at 3 months (middle 
panel), while after 9 months only mesial and polar temporal lobes hyperintensities mildly persisted 
bilaterally (right panel). 
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Fig 2 Deep sequencing analysis of viral RNA isolated from the cerebrospinal fluid of our 
patient at the onset of neurological symptoms 
The V1-V3 region of the HIV env was sequenced using the Primer ID method (Zhou et al. 2015). 
The diverse nature of this population indicates that it is being produced by a large number of HIV 
infected cells within the CNS. 
